ORIC reports Q1 cash $208.9M; three Phase 1b data readouts expected H2 2023

Oric Pharmaceuticals, Inc.

2023-Q1 EPS reported -$0.53

Cash and investments $208.9M as of March 31, 2023; funds operations into H1 2025.
R&D expenses $19.5M (up $2.7M YoY) driven by clinical and discovery program advancement.
G&A expenses $6.2M, down $0.3M YoY.
Initial Phase 1b data expected H2 2023 for ORIC-533 (myeloma), ORIC-114 (EGFR/HER2), and ORIC-944 (prostate).
Preclinical data for ORIC-944 biomarker strategy and PLK4 program presented at AACR 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.1

Oric Pharmaceuticals, Inc. reported financial results for the quarter ended March 31, 2023.

Period: the quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 8, 2023, ORIC Pharmaceuticals, Inc. issued a press release announcing its financial results for the fiscal quarter ended March 31, 2023.

View on SEC.gov

Browse all earnings releases →

Oric Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-018807

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.